Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study
<p>Objectives: To evaluate the efficacy and safety of different doses and regimens of filgotinib, an oral JAK1 inhibitor, as add-on treatment to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and inadequate response to MTX.</p> <p>Methods: In this 24-week phas...
| Hoofdauteurs: | , , , , , , , , , , |
|---|---|
| Formaat: | Journal article |
| Gepubliceerd in: |
BMJ Publishing Group
2016
|